A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 160
- Registration Number
- NCT04666610
- Locations
- πΊπΈ
N01269 103, Loxahatchee Groves, Florida, United States
πΊπΈN01269 115, Birmingham, Alabama, United States
πΊπΈN01269 118, Long Beach, California, United States
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 496
- Registration Number
- NCT04658186
- Locations
- πΊπΈ
Pd0053 50529, Baltimore, Maryland, United States
πΊπΈPd0053 50547, Baltimore, Maryland, United States
πΊπΈPd0053 50255, Columbus, Ohio, United States
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 19
- Registration Number
- NCT04658199
- Locations
- π§πͺ
Psp002 40002, Leuven, Belgium
π§πͺPsp002 40122, Edegem, Belgium
π©πͺPsp002 40277, Bochum, Germany
A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 62
- Registration Number
- NCT04651153
- Locations
- π³π±
Up0092 201, Leiden, Netherlands
π¬π§Up0092 101, London, United Kingdom
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 165
- Registration Number
- NCT04650854
- Locations
- π¨π³
Mg0007 20086, Taipei City, Taiwan
πΊπΈMg0007 50073, Tampa, Florida, United States
πΊπΈMg0007 50122, Miami, Florida, United States
A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 107
- Registration Number
- NCT04643457
- Locations
- π§π¬
Up0089 301, Sofia, Bulgaria
π§π¬Up0089 304, Sofia, Bulgaria
π©πͺUp0089 408, Heidelberg, Germany
A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- UCB Biopharma SRL
- Registration Number
- NCT04643483
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 48
- Registration Number
- NCT04627285
- Locations
- πΊπ¦
Ep0151 606, Kiev, Ukraine
π¬πͺEp0151 620, Tbilisi, Georgia
πΊπ¦Ep0151 682, Uzhgorod, Ukraine
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 43
- Registration Number
- NCT04596995
- Locations
- πΊπΈ
Tp0004 50243, Boston, Massachusetts, United States
π¨π³Tp0004 20185, Jinan, China
ππΊTp0004 40202, GyΕr, Hungary
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
- Conditions
- Interventions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 32
- Registration Number
- NCT04519645
- Locations
- πΊπΈ
Sp0968 112, Iowa City, Iowa, United States
π¦πΊSp0968 302, Parkville, Australia
πΊπΈSp0968 101, La Jolla, California, United States